Montelukast (Singulair)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Asthma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
US
  • Exercise-Induced Bronchoconstriction (EIB) SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older.
  • Allergic Rhinitis SINGULAIR is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. Because the benefits of SINGULAIR may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see Warnings and Precautions (5.1) ] , reserve use for patients who have an inadequate response or intolerance to alternative therapies.
Product first approved 1998Outside this platform's coverageFDA label

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (69)
Asthma
NCT03372473 · Innovacion y Desarrollo de Estrategias en Salud
2016-01-10 – 2017-06-30 · Asthma in Children
What this study did
NCT01606306 · Milton S. Hershey Medical Center
2013-02 – 2015-04 · Asthma, Wheezing
What this study did
NCT01266772 · Medical University of Lodz
2011-01 – 2013-12 · Bronchial Asthma
What this study did
NCT00395304 · Milton S. Hershey Medical Center
2007-03 – 2011-12 · Asthma
What this study did
NCT00284856 · Organon and Co
2006-05 – 2010-04 · Asthma
What this study did
NCT00337675 · Organon and Co
2006-10 – 2009-08 · Asthma
What this study did
NCT00462592 · Hamilton Health Sciences Corporation
2007-03 – 2009-06 · Asthma
What this study did
NCT00127166 · Organon and Co
2005-12 – 2008-11 · Exercise Induced Asthma
What this study did
NCT00565955 · All India Institute of Medical Sciences
2007-03 – 2008-10 · Bronchial Asthma
What this study did
NCT00540839 · Organon and Co
2007-11 – 2008-03 · Asthma, Bronchial
What this study did
NCT00117338 · Organon and Co
2005-07 – 2008-03 · Asthma
What this study did
NCT00442338 · Organon and Co
2007-03 – 2007-08 · Asthma
What this study did
NCT00289874 · Organon and Co
2006-03 – 2007-07 · Asthma
What this study did
NCT00229970 · Organon and Co
2005-09 – 2007-06 · Asthma
What this study did
NCT00328718 · GlaxoSmithKline
2005-10 – 2007-04 · Asthma
What this study did
NCT00504946 · Medical University of Lodz
2005-09 – 2007-03 · Asthma
What this study did
NCT00092989 · Organon and Co
2004-07 – 2007-03 · Asthma
What this study did
NCT00116324 · Brigham and Women's Hospital
2003-04 – 2006-12 · Asthma
What this study did
NCT00461032 · Organon and Co
2006-06 – 2006-11 · Asthma
What this study did
NCT00245570 · Organon and Co
2005-12 – 2006-09 · Asthma, Exercise-Induced
What this study did
NCT00675285 · Catholic University of the Sacred Heart
2005-09 – 2006-07 · Asthma
What this study did
NCT00445107 · Organon and Co
2005-11-01 – 2006-05-17 · Asthma
What this study did
NCT00090142 · Organon and Co
2004-05 – 2004-10 · Asthma, Exercise-Induced
What this study did
NCT00092144 · Organon and Co
2004-02-26 – 2004-06-15 · Asthma
What this study did
NCT00045955 · Sanofi
2002-02 – 2003-11 · Asthma
What this study did
NCT00092131 · Organon and Co
2003-06 – 2003-11 · Asthma, Exercise-Induced
What this study did
NCT00092885 · Organon and Co
2003-03 – 2003-10 · Rhinitis, Allergic, Seasonal, Asthma, Bronchial
What this study did
NCT00092105 · Organon and Co
2002-04-01 – 2003-01-28 · Asthma, Bronchial, Rhinitis, Allergic, Perennial
What this study did
NCT00700661 · Organon and Co
2001-01 – 2002-12 · Asthma
What this study did
NCT00162864 · Kaiser Permanente
1999-12 – 2002-04 · Asthma, COPD
What this study did
NCT00943397 · Organon and Co
2001-04 – 2001-11 · Asthma
What this study did
NCT00968201 · Organon and Co
1997-12 – 2001-03 · Asthma
What this study did
Other / comorbidity
NCT05405166 · Sanofi
2022-06-23 – 2027-10-22 · Plasma Cell Myeloma Recurrent
What this study did
NCT03770923 · Sherief Abd-Elsalam
2018-10-01 – 2027-10 · Rheumatoid Arthritis
What this study did
NCT07320625 · Shanghai Zhongshan Hospital
2026-02-01 – 2027-05-01 · Myocardial Infarction (MI)
What this study did
NCT06340984 · South Valley University
2024-06 – 2025-02 · Acne Vulgaris
What this study did
NCT02793375 · Children's Hospital Medical Center, Cincinnati
2018-08-02 – 2024-11-19 · Pain
What this study did
NCT04885530 · Susanna Naggie, MD
2021-06-08 – 2024-04-29 · Covid19
What this study did
NCT05894577 · Susanna Naggie, MD
2023-01-27 – 2024-01-01 · Covid19
What this study did
NCT04277702 · Jagiellonian University
2020-05 – 2023-12 · Peripheral Arterial Disease, Peripheral Vascular Diseases, Lower Limb Ischemia, Atherosclerosis of Artery
What this study did
NCT04695704 · Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
2021-08-11 – 2023-08-28 · Covid19, SARS (Disease)
What this study did
NCT05362474 · University of Colorado, Denver
2022-07-01 – 2023-06-20 · Diabetic Kidney Disease
What this study did
NCT03545997 · University Hospital, Grenoble
2019-11-29 – 2020-03-20 · Sleep Apnea, Obstructive
What this study did
NCT01702701 · Medical College of Wisconsin
2012-01 – 2017-07-20 · Eosinophilic Esophagitis, Dysphagia
What this study did
NCT01089647 · Romaker & Associates
2010-09 – 2014-06 · Obstructive Sleep Apnea
What this study did
Phase 2/3 (11)
Asthma
NCT00115297 · University of Massachusetts, Worcester
2004-09 – 2016-10 · Lung Diseases, Asthma
What this study did
NCT01951898 · Kurume University
2012-06 – 2015-05 · Asthma
What this study did
NCT00494572 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2006-12 – 2010-10 · Status Asthmaticus, Asthma
What this study did
NCT00491790 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2006-12 – 2010-10 · Status Asthmaticus, Asthma
What this study did
NCT00311051 · Research Center Borstel
2005-04 – 2007-04 · Asthma
What this study did
Other / comorbidity
NCT06747130 · Phramongkutklao College of Medicine and Hospital
2025-01-31 – 2027-01 · Dengue, Montelukast, Transaminases
What this study did
NCT06113640 · Mostafa Bahaa
2023-11-05 – 2026-08-20 · Parkinson Disease
What this study did
NCT04389411 · McGill University
2022-11-01 – 2025-02 · COVID-19
What this study did
NCT04351698 · Great Ormond Street Hospital for Children NHS Foundation Trust
2023-10-16 – 2024-09-30 · Anemia, Sickle Cell, Sleep-Disordered Breathing
What this study did
NCT04673422 · Phramongkutklao College of Medicine and Hospital
2021-01-15 – 2023-06-17 · Dengue, Dengue With Warning Signs, Dengue Shock Syndrome
What this study did
NCT05293132 · Ain Shams University
2022-02-01 – 2023-06-01 · Sepsis
What this study did
Phase 2 (36)
Asthma
NCT03277170 · Vanderbilt University Medical Center
2025-09-01 – 2029-09-05 · Asthma; Status, Asthma in Children, Asthma Acute, Asthma Attack, Acute Asthma Exacerbation
What this study did
NCT05819541 · Vanderbilt University Medical Center
2023-10-20 – 2026-03-26 · Status Asthmaticus
What this study did
NCT01656395 · Merck Sharp & Dohme LLC
2012-08-23 – 2014-07-08 · Asthma
What this study did
NCT00961155 · Medical University of Lodz
2009-08 – 2014-06 · Asthma
What this study did
NCT01765192 · AstraZeneca
2013-02 – 2013-10 · Asthma
What this study did
NCT00947453 · University of East Anglia
2009-07 – 2011-12 · Asthma
What this study did
NCT01241422 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010-11 – 2011-06 · Asthma
What this study did
NCT00543686 · Johann Wolfgang Goethe University Hospital
2007-08 – 2009-02 · Asthma
What this study did
NCT00213252 · The Hospital for Sick Children
2005-09 – 2008-02 · Asthma, Bronchial
What this study did
NCT00783601 · Merck Sharp & Dohme LLC
2004-10 – 2005-05 · Asthma
What this study did
Other / comorbidity
NCT05704049 · Sanofi
2023-04-05 – 2028-05-12 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT05922761 · Dana-Farber Cancer Institute
2024-05-31 – 2027-12-31 · Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease
What this study did
NCT07537868 · October 6 University
2026-04-20 – 2027-10 · Acute Myocardial Infarction (AMI)
What this study did
NCT05663866 · Janssen Research & Development, LLC
2023-05-18 – 2027-09-30 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT07770464 · Pakistan Institute of Medical Sciences
2026-01-01 – 2026-09-30 · Acute Bronchiolitis
What this study did
NCT04294641 · National Cancer Institute (NCI)
2021-05-10 – 2024-10-01 · Chronic GVHD
What this study did
NCT04198623 · University of California, San Francisco
2020-03-20 – 2024-07-31 · Infusion Reaction, Monoclonal Antibody
What this study did
NCT03402503 · IntelGenx Corp.
2018-11-26 – 2024-04-03 · Alzheimer Disease
What this study did
NCT03794037 · Benha University
2018-12-05 – 2023-12 · Ovarian Hyperstimulation Syndrome
What this study did
NCT05447520 · Noha Mansour
2021-12-15 – 2022-12-30 · Rheumatoid Arthritis
What this study did
NCT03991988 · Emory University
2019-09-25 – 2022-11-18 · Alzheimer Disease
What this study did
NCT04718285 · Bahçeşehir University
2021-05-15 – 2022-06-01 · COVID-19, SARS-CoV-2
What this study did
NCT04374981 · Damanhour University
2019-07-01 – 2019-12-01 · Food-drug Interaction
What this study did
NCT01960413 · Vanderbilt University Medical Center
2013-11 – 2018-03 · Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
What this study did
NCT00656058 · National Cancer Institute (NCI)
2008-06-17 – 2018-02-22 · Bronchiolitis Obliterans, Chronic Graft Versus Host Disease, Leukotriene, Montelukast, Stem Cell Transplant
What this study did
NCT02108886 · Université de Sherbrooke
2011-12 – 2015-12 · Preterm Labor
What this study did
NCT01307462 · Stephanie Lee
2011-06 – 2015-12 · Bronchiolitis Obliterans
What this study did
NCT02352545 · Beijing Chao Yang Hospital
2014-08 – 2015-10 · Cough
What this study did
NCT01432080 · Maisonneuve-Rosemont Hospital
2011-09 – 2013-12-30 · Respiratory Tract Infections, Bronchiolitis Obliterans, Cryptogenic Organizing Pneumonia, Lung Diseases, Interstitial
What this study did
NCT01717625 · Ajou University School of Medicine
2011-11 – 2013-10 · Premature Birth, Infant, Very Low Birth Weight, Bronchopulmonary Dysplasia
What this study did
NCT00599534 · University of Louisville
2007-12 – 2009-12 · Sleep Apnea
What this study did
NCT00394160 · Organon and Co
2004-12 – 2005-10 · Bronchiolitis
What this study did
NCT00446186 · Organon and Co
2004-02 – 2004-03 · Rhinitis Allergic
What this study did
NCT00394069 · Organon and Co
2003-07 – 2003-12 · Bronchiolitis
What this study did
Phase 1/2 (4)
Other / comorbidity
NCT07101640 · Duke University
2026-02-23 – 2028-06-30 · Bronchopulmonary Dysplasia (BPD), Premature Births, Critical Illness
What this study did
NCT05143502 · Assiut University
2022-01-01 – 2024-03-01 · Montelukast, Chronic Rhinosinusitis With Nasal Polyps
What this study did
NCT04294459 · Sanofi
2020-06-18 – 2022-05-02 · Immune System Disorder
What this study did
NCT04080947 · Sadat City University
2019-08-01 – 2022-03-15 · Steatohepatitis, Nonalcoholic
What this study did
Phase 1 (50)
Asthma
NCT01621386 · Hal C Charles
2013-01 – 2016-03 · Asthma
What this study did
NCT02658422 · GlaxoSmithKline
2015-08-18 – 2015-09-21 · Respiratory Disorders, Asthma and Rhinitis
What this study did
NCT02029313 · PharmaKing
2013-11 – 2014-03 · Asthma and Allergic Rhinitis
What this study did
NCT01061333 · Merck Sharp & Dohme LLC
2010-06 – 2011-03 · Asthma
What this study did
NCT01863654 · GlaxoSmithKline
2010-05-16 – 2010-05-26 · Asthma
What this study did
NCT01943942 · GlaxoSmithKline
2010-05-16 – 2010-05-26 · Asthma
What this study did
NCT00676468 · Indiana University
2008-09 – 2009-04 · Asthma
What this study did
NCT00739297 · Organon and Co
2008-07 – 2008-12 · Chronic Asthma
What this study did
NCT00664937 · Organon and Co
2007-05 – 2008-10 · Asthma, Exercise-induced
What this study did
NCT01659892 · Roxane Laboratories
2008-08 – 2008-08 · Asthma
What this study did
NCT01659905 · Roxane Laboratories
2008-08 – 2008-08 · Asthma
What this study did
NCT01659918 · Roxane Laboratories
2008-02 – 2008-02 · Asthma
What this study did
NCT01659931 · Roxane Laboratories
2008-02 – 2008-02 · Asthma
What this study did
NCT00273013 · GlaxoSmithKline
2004-11-15 – 2005-10-28 · Asthma
What this study did
Other / comorbidity
NCT07409714 · University of Colorado, Denver
2026-10-12 – 2031-12 · Type 2 Diabetes
What this study did
NCT05992311 · Baylor College of Medicine
2025-08-15 – 2028-08 · Gulf War Syndrome
What this study did
NCT04572256 · Austin V Stone
2021-02-01 – 2027-06 · ACL Injury, Meniscus Tear, Post-traumatic Osteoarthritis
What this study did
NCT07838987 · Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2023-12-21 – 2026-06-30 · Healthy
What this study did
NCT06887673 · University of South Florida
2025-03 – 2026-03 · Colorectal Cancer, Sarcoma, Brain Tumors, Endometrial Cancer, Ovarian Cancer
What this study did
NCT05381207 · Assiut University
2022-10 – 2024-10 · Allergic Rhinitis
What this study did
NCT01998971 · Janssen Research & Development, LLC
2014-02-18 – 2024-01-11 · Multiple Myeloma
What this study did
NCT05607446 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2022-09-14 – 2023-12-14 · Allergic Rhinitis
What this study did
NCT05852769 · Bristol-Myers Squibb
2023-05-31 – 2023-08-24 · Healthy Volunteers
What this study did
NCT04075110 · Sadat City University
2019-07-01 – 2023-04-10 · Obesity; Endocrine; Diabetes Type 2
What this study did
NCT04474327 · Mansoura University Children Hospital
2020-07-24 – 2021-02-10 · Neonatal Sepsis
What this study did
NCT03131973 · Bristol-Myers Squibb
2017-05-13 – 2017-11-10 · Rheumatoid Arthritis
What this study did
NCT03371849 · Hanmi Pharmaceutical Company Limited
2017-07-19 – 2017-08-03 · Healthy
What this study did
NCT00511316 · Mayo Clinic
2007-08 – 2015-09 · Eosinophilic Esophagitis
What this study did
NCT02321748 · Maruho Europe Limited
2014-12 – 2015-04 · Healthy
What this study did
NCT02227173 · Bristol-Myers Squibb
2014-09 – 2014-11 · Drug-drug Interaction Study
What this study did
NCT02480049 · Genuine Research Center, Egypt
2014-08 – 2014-08 · Healthy
What this study did
NCT02479854 · Genuine Research Center, Egypt
2014-04 – 2014-04 · Healthy
What this study did
NCT01651481 · Hanmi Pharmaceutical Company Limited
2012-07 – 2012-12 · Rhinitis
What this study did
NCT01491503 · Hanmi Pharmaceutical Company Limited
2011-11 – 2012-01 · Healthy
What this study did
NCT00492102 · Children's Hospital Medical Center, Cincinnati
2007-03 – 2011-06 · Bronchopulmonary Dysplasia
What this study did
NCT01691456 · Dr. Reddy's Laboratories Limited
2011-01 – 2011-02 · Healthy
What this study did
NCT01691469 · Dr. Reddy's Laboratories Limited
2011-01 – 2011-02 · Healthy
What this study did
NCT01671709 · Dr. Reddy's Laboratories Limited
2010-02 – 2010-03 · Healthy
What this study did
NCT01671722 · Dr. Reddy's Laboratories Limited
2010-02 – 2010-03 · Healthy
What this study did
NCT01674517 · Dr. Reddy's Laboratories Limited
2010-02 – 2010-02 · Healthy
What this study did
NCT01674504 · Dr. Reddy's Laboratories Limited
2010-01 – 2010-01 · Healthy
What this study did
NCT01928069 · Torrent Pharmaceuticals Limited
est. completion 2009-12 · Healthy
What this study did
NCT01928056 · Torrent Pharmaceuticals Limited
est. completion 2009-12 · Healthy
What this study did
NCT01931501 · Torrent Pharmaceuticals Limited
est. completion 2008-02 · Healthy
What this study did
NCT01931514 · Torrent Pharmaceuticals Limited
est. completion 2008-02 · Healthy
What this study did
Phase 4 (83)
Asthma
NCT04815187 · House Ear Institute
2021-06-07 – 2025-12-31 · Meniere Disease, Allergic Rhinitis, Vertigo
What this study did
NCT07533565 · Kafrelsheikh University
2024-07-01 – 2025-10-01 · Cirrhosis, Asthma
What this study did
NCT03380975 · Clinision
2018-08-28 – 2019-06-30 · Asthma and Allergic Rhinitis
What this study did
NCT03096327 · PharmEvo Pvt Ltd
2017-05-01 – 2018-05-30 · Asthma
What this study did
NCT01696214 · University of California, San Diego
2012-10 – 2016-11 · Asthma
What this study did
NCT02635334 · Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.
2015-11 – 2016-06 · Asthma
What this study did
NCT01618929 · Hacettepe University
2013-03 – 2016-05 · Bronchial Asthma, Food Allergy, Children
What this study did
NCT01404013 · The First Affiliated Hospital of Guangzhou Medical University
2012-02 – 2014-08 · Asthma
What this study did
NCT01016847 · Duke University
2010-01 – 2013-11 · Asthma
What this study did
NCT00875082 · Universita di Verona
2010-02 – 2013-04 · Asthma
What this study did
NCT03369119 · Kecioren Education and Training Hospital
2011-08 – 2012-12 · Acute Asthma, Acute Wheezy Bronchitis
What this study did
NCT01147510 · Ajou University School of Medicine
2010-07 – 2012-09 · Persistent Asthma, Elderly
What this study did
NCT00699062 · Chinese Academy of Medical Sciences
2010-01 – 2012-01 · Asthma
What this study did
NCT01725360 · Cantonal Hospital, Baselland
2007-01 – 2012-01 · Asthma
What this study did
NCT01121016 · Guangzhou Medical University
2010-06 – 2011-06 · Nonasthmatic Eosinophilic Bronchitis
What this study did
NCT00712335 · Inje University
2007-02 – 2011-05 · Asthmatic Smokers, Non-asthmatic Smokers
What this study did
NCT01304901 · Kecioren Education and Training Hospital
2010-04 – 2010-12 · Asthma, Acute Asthma
What this study did
NCT00770900 · University of Brasilia
2008-09 – 2009-12 · Asthma
What this study did
NCT00721240 · Marien Hospital Wesel
2006-02 – 2009-06 · Asthma
What this study did
NCT00487773 · Medical University of Lodz
2007-09 – 2008-09 · Asthma
What this study did
NCT00935415 · Universita di Verona
2007-01 – 2008-08 · Exercise-Induced Asthma, Asthma
What this study did
NCT00545844 · Organon and Co
2007-04-01 – 2008-01-01 · Asthma
What this study did
NCT00296491 · GlaxoSmithKline
2005-09 – 2007-10 · Asthma
What this study did
NCT00442559 · Organon and Co
2005-01 – 2007-10 · Asthma, Allergic Rhinitis
What this study did
NCT00559546 · University of Helsinki
2007-03 – 2007-07 · Seasonal Allergic Rhinitis, Allergic Conjunctivitis, Atopic Eczema, Asthma
What this study did
NCT00296530 · GlaxoSmithKline
2005-09 – 2007-07 · Asthma
What this study did
NCT00471809 · National Heart, Lung, and Blood Institute (NHLBI)
2006-03 – 2007-03 · Asthma
What this study did
NCT00490243 · Medical University of Lodz
2003-07 – 2006-10 · Asthma
What this study did
NCT00913328 · Hvidovre University Hospital
2002-08 – 2006-10 · Asthma
What this study did
NCT00156819 · JHSPH Center for Clinical Trials
2003-06 – 2006-08 · Asthma
What this study did
NCT00148408 · American Lung Association Asthma Clinical Research Centers
2003-12 – 2005-12 · Asthma
What this study did
NCT00196547 · Firestone Institute for Respiratory Health
2005-09 – 2005-11 · Asthma
What this study did
NCT00380705 · Organon and Co
2005-03-18 – 2005-07-29 · Asthma, Rhinitis Allergic
What this study did
NCT00157937 · Organon and Co
2003-02 – 2005-06 · Asthma, Allergic Rhinitis
What this study did
NCT01011452 · University of East Anglia
2001-05 – 2004-10 · Acute Asthma Exacerbation
What this study did
NCT00756418 · Organon and Co
2003-06-01 – 2004-08-28 · Asthma
What this study did
NCT00446056 · Organon and Co
2003-09-25 – 2004-06-16 · Asthma
What this study did
NCT00092092 · Organon and Co
2002-10 – 2004-06 · Asthma, Bronchial
What this study did
NCT00545324 · Organon and Co
2002-09 – 2003-12 · Asthma
What this study did
NCT00395408 · Organon and Co
2000-06 – 2003-12 · Asthma
What this study did
Other / comorbidity
NCT07685886 · University of Colorado, Denver
2026-09-01 – 2031-08-31 · Diabetes, Kidney Disease, Vascular Disease, Retinopathy
What this study did
NCT07532993 · Liaquat National Hospital & Medical College
2026-09 – 2027-05 · Allergic Rhinitis (AR)
What this study did
NCT05498116 · University of Colorado, Denver
2023-01-26 – 2027-04 · Albuminuria
What this study did
NCT02655562 · Beijing Chao Yang Hospital
2016-04 – 2026-02 · Coughing
What this study did
NCT04762472 · Chinese University of Hong Kong
2023-09 – 2025-12-30 · Atherosclerosis, Coronary
What this study did
NCT06019728 · Sanofi
2023-11-10 – 2024-10-25 · Fabry's Disease
What this study did
NCT04613180 · Samarkand State Medical Institute
2018-01-03 – 2024-06-01 · Acute Bronchiolitis
What this study did
Early phase / not applicable (36)
Asthma
NCT04322422 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-06-01 – 2022-12-31 · Asthma, Chest Syndrome, Clinical Anxiety, Clinical Depression, Lung Function, Quality of Life, Eosinophilia, Nitric Oxide, Airway Responsiveness, Induced Sputum
What this study did
NCT02758873 · University of Sussex
2016-02 – 2019-07 · Asthma
What this study did
NCT01581710 · CHA University
2012-05 – 2015-12 · Mild Persistent Asthma
What this study did
NCT01841164 · Karolinska University Hospital
2012-05 – 2014-12 · Asthma
What this study did
NCT00513760 · Nemours Children's Clinic
2007-06 – 2014-12 · Asthma
What this study did
NCT01224964 · Universitaire Ziekenhuizen KU Leuven
2011-01 – 2014-10 · Asthmatic Patients
What this study did
NCT01329939 · Northwell Health
2011-04 – 2014-09 · Asthma, Obesity, Inflammation
What this study did
NCT01770899 · Corrie Fletcher
2013-01 – 2013-12 · Status Asthmaticus
What this study did
NCT01414868 · Guangzhou Institute of Respiratory Disease
2010-03 – 2010-09 · Bronchial Asthma
What this study did
NCT00655616 · University of Dundee
2007-08 – 2009-12 · Asthma
What this study did
NCT01055041 · Government Medical College, Bhavnagar
2008-12 – 2009-07 · Moderate to Severe Persistent Bronchial Asthma
What this study did
NCT00359073 · University of Wisconsin, Madison
2006-10 – 2009-01 · Asthma
What this study did
NCT00424580 · University of Saskatchewan
2007-01 – 2007-08 · Asthma
What this study did
NCT00319488 · National Heart, Lung, and Blood Institute (NHLBI)
2004-02 – 2006-11 · Asthma, Lung Diseases
What this study did
NCT00353184 · Washington University School of Medicine
2001-09 – 2005-02 · Asthma
What this study did
NCT00943683 · Organon and Co
2000-08 – 2001-02 · Asthma
What this study did
Other / comorbidity
NCT05959889 · Damanhour University
2023-03-01 – 2024-12-01 · Breast Cancer, Doxorubicin Induced Cardiotoxicity
What this study did
NCT04561687 · Shiraz University of Medical Sciences
2020-01-16 – 2021-12-15 · Allergic Rhinitis
What this study did
NCT05447039 · Assiut University
2020-09-01 – 2021-03-30 · Post COVID-19
What this study did
NCT04818723 · Nishtar Medical University
2019-02-01 – 2020-05-30 · Nephrotic Syndrome
What this study did
NCT05531994 · Qilu Pharmaceutical Co., Ltd.
2018-11-27 – 2019-05-14 · Healthy Volunteers
What this study did
NCT05528198 · Qilu Pharmaceutical Co., Ltd.
2018-12-28 – 2019-05-14 · Healthy Volunteers
What this study did
NCT03039101 · Mitchell Grayson
2017-09-06 – 2018-07-16 · Nasal Allergy
What this study did
NCT01967498 · Tel-Aviv Sourasky Medical Center
2013-11 – 2016-05 · Chronic Otitis Media With Effusion, Conductive Hearing Loss
What this study did
NCT00375232 · Indiana University
started 2006-10 · Exercise-Induced Bronchospasm
What this study did
NCT02559388 · Shiraz University of Medical Sciences
2015-04 – 2015-08 · Renal Insufficiency, Chronic
What this study did
NCT01458418 · Children's Mercy Hospital Kansas City
2011-12 – 2015-02 · Eosinophilic Esophagitis
What this study did
NCT01240889 · Creighton University
2010-11 – 2011-07 · Allergy
What this study did
NCT00863317 · Medical College of Wisconsin
2008-12 – 2011-07 · Bronchiolitis
What this study did
NCT01370187 · Hormozgan University of Medical Sciences
2010-07 – 2011-06 · Bronchiolitis, Wheezing, Cough
What this study did
NCT00903357 · Pyun BokYang
2009-08 – 2011-04 · Atopic Dermatitis
What this study did
NCT00379808 · University of Florida
2006-07 – 2009-08 · Coronary Heart Disease
What this study did
NCT00406861 · The Leprosy Mission Bangladesh
2006-12 – 2009-06 · Erythema Nodosum Leprosum, Leprosy
What this study did
NCT00814281 · Marywood University
2007-05 – 2009-05 · Airway Inflammation
What this study did
NCT00524693 · Ziv Hospital
started 2006-01 · Bronchiolitis
What this study did
NCT00148603 · Children's Mercy Hospital Kansas City
2005-09 – 2006-12 · Eosinophilic Gastroenteritis, Dyspepsia
What this study did
Used as active comparator (23)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Asthma
NCT02104674 · Hoffmann-La Roche
2014-06-07 – 2016-01-22 · Asthma
What this study did
Other / comorbidity
NCT01640535 · Hanmi Pharmaceutical Company Limited
2012-06 – 2013-02 · Perennial Allergic Rhinitis
What this study did
Phase 2 (13)
Asthma
NCT01730027 · Pulmagen Therapeutics
2013-04 – 2014-12 · Asthma
What this study did
NCT01424124 · Yuhan Corporation
2011-11 – 2014-01 · Asthma
What this study did
NCT01437735 · Novartis Pharmaceuticals
2011-08 – 2013-11 · Asthma
What this study did
NCT01551147 · Ono Pharma USA Inc
2012-06 – 2013-04 · Asthma
What this study did
NCT01536041 · Ono Pharma USA Inc
2012-03 – 2012-11 · Asthma
What this study did
NCT01147744 · GlaxoSmithKline
2010-06-28 – 2011-10-06 · Asthma
What this study did
NCT01103349 · Boehringer Ingelheim
2010-04-20 – 2011-08-09 · Asthma
What this study did
NCT00936624 · SK Chemicals Co., Ltd.
2009-07 – 2011-05 · Asthma
What this study did
Other / comorbidity
Phase 1 (1)
Asthma
NCT00856687 · Pfizer
2009-04 – 2009-12 · Asthma
What this study did
Phase 4 (5)
Asthma
NCT02761252 · Menarini International Operations Luxembourg SA
2016-04-13 – 2016-11-24 · Seasonal Allergic Rhinoconjunctivitis, Asthma
What this study did
NCT01526161 · Professor Warren Lenney
2009-04 – 2011-01 · Asthma
What this study did
NCT00380484 · Children´s Clinic, Randers
2006-09 – 2008-02 · Asthma
What this study did
NCT00641472 · AstraZeneca
2002-10 – 2005-02 · Asthma
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT06597682 · Huashan Hospital
2025-03 – 2027-07 · Post-acute Sequelae of SARS-COV-2 Infection
What this study did
NCT02303600 · Beijing Chao Yang Hospital
2014-08 – 2015-08 · Coughing
What this study did
Appears in other studies (12)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Asthma
NCT02483975 · GlaxoSmithKline
2015-10-09 – 2016-06-21 · Asthma
What this study did
Other / comorbidity
NCT04270409 · Sanofi
2020-06-16 – 2033-10-21 · Plasma Cell Myeloma
What this study did
Phase 2 (4)
Asthma
NCT02720081 · Merck Sharp & Dohme LLC
2016-05-11 – 2017-09-06 · Asthma
What this study did
Other / comorbidity
NCT05896228 · Benjamin T Diamond, MD
2024-02-20 – 2031-03-01 · Refractory Multiple Myeloma, Relapsed Multiple Myeloma
What this study did
NCT06356571 · Sanofi
2025-03-17 – 2027-07-15 · Plasma Cell Myeloma Refractory
What this study did
NCT04268498 · University of Miami
2020-02-11 – 2027-02-01 · Multiple Myeloma
What this study did
Phase 1 (2)
Other / comorbidity
NCT02762123 · Bristol-Myers Squibb
2016-05 – 2016-08 · Rheumatoid Arthritis
What this study did
NCT02456844 · Bristol-Myers Squibb
2015-05 – 2015-07 · Rheumatoid Arthritis
What this study did
Phase 4 (4)
Asthma
NCT02889809 · GlaxoSmithKline
2017-07-10 – 2021-06-04 · Asthma
What this study did
NCT02110654 · First Affiliated Hospital, Sun Yat-Sen University
2014-06 – 2020-11-01 · Sinusitis, Nasal Polyps, Asthma
What this study did
NCT03269318 · Brighton and Sussex University Hospitals NHS Trust
2017-07-01 – 2019-08-30 · Asthma
What this study did
Other / comorbidity

Competitive landscape

This drug's own stage for Asthma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Montelukast (Singulair): this drugApprovedSmall moleculeCysteinyl leukotriene receptor 1 (CysLT1)Weak signal
NCT00489346: Primary endpoint (percentage of asthma rescue-free days over 12 months): montelukast 5mg QD (n=495) was non-inferior to fluticasone 100mcg BID (n=499) — 495+499=994, exactly matching this record's enrollment. LS mean difference -2.8% (95% CI -4.7% to -0.9%), within the pre-specified -7% noninferiority margin.
Albuterol (Armstrong Albuterol HFA)ApprovedSmall moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Albuterol (Ventolin)ApprovedSmall moleculeBeta-2 adrenergic receptorWeak signalNo reviewed efficacy summary in this indication
Albuterol / Budesonide (Airsupra)ApprovedCombinationBeta-2 adrenergic receptor, Glucocorticoid receptorReliable signal
NCT05505734: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212
NCT03769090: Number of Participants With a Severe Asthma Exacerbation Event (From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.): BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) 207/1013 | BDA MDI 80/180 μg (Full Analysis Set) 241/1054 vs AS MDI 180 μg (Full Analysis Set; >=12 Years) 266/1014 | AS MDI 180 μg (Full Analysis Set) 276/1056
Albuterol Sulfate (Amphastar)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Albuterol Sulfate (Proventil HFA)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
AminophyllineApprovedSmall moleculePhosphodiesterase (multi-subtype)not yet gradedNo reviewed efficacy summary in this indication
Beclomethasone (QVAR)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT02040766: Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results).
Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signalNo reviewed efficacy summary in this indication
Benralizumab (Fasenra)ApprovedMonoclonal antibodyIL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophilsReliable signal
NCT03170271: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) (Baseline (Week 0) up to Week 24): Benralizumab 0.94 Events/year (95% CI 0.79 to 1.12) | Placebo 1.86 Events/year (95% CI 1.54 to 2.24)
NCT01928771: Annual asthma exacerbation rate: 0.73 events/year with benralizumab 30 mg q4w vs 1.33 with placebo (rate ratio 0.55, 95% CI 0.42-0.71; p<0.001); 0.65 events/year with benralizumab 30 mg q8w vs 1.33 with placebo (rate ratio 0.49, 95% CI 0.37-0.64; p<0.001).
Budesonide (Pulmicort)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Pulmicort Flexhaler)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide / Formoterol Fumarate (SYMBICORT)ApprovedCombinationGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00646321: Evening PEF (primary) better with once- or twice-daily budesonide/formoterol than budesonide alone (P<or=.027).
Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere)ApprovedSmall moleculeGlucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicPartial signal
NCT04609878: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.281 Liters (Standard Error 0.018) | BGF MDI 320/28.8/9.6 μg BID 0.316 Liters (Standard Error 0.014) vs BFF MDI 320/9.6 μg BID 0.249 Liters (Standard Error 0.014) | Symbicort® pMDI 320/9 μg BID 0.22 Liters (Standard Error 0.014)
NCT04609904: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.374 Liters (Standard Error 0.019) | BGF MDI 320/28.8/9.6 μg BID 0.354 Liters (Standard Error 0.015) vs BFF MDI 320/9.6 μg BID 0.219 Liters (Standard Error 0.015) | Symbicort® 320/9 μg BID 0.239 Liters (Standard Error 0.015)
Ciclesonide (Alvesco)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT00174720: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone
NCT00163397: Change in FEV1: non-inferiority of ciclesonide to budesonide demonstrated (one-sided p = 0.0021), confirmed in the ITT analysis
DepemokimabApprovedMonoclonal antibodyIL-5Partial signal
NCT04719832: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58)
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaPartial signal
NCT03782532: Change in pre-bronchodilator FEV1, baseline to Week 12: LS mean difference 0.31 L favoring dupilumab vs placebo (95% CI 0.23-0.39); p<0.0001 (primary analysis population, n=414).
Fluticasone Furoate (Arnuity Ellipta)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT00603278: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409)
NCT00603382: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 25 µg OD 0.239 Liters (Standard Error 0.0428) | GW685698X 50 µg OD 0.266 Liters (Standard Error 0.042) | GW685698X 100 µg OD 0.341 Liters (Standard Error 0.0396) | GW685698X 200 µg OD 0.367 Liters (Standard Error 0.0428) vs Placebo 0.137 Liters (Standard Error 0.0428) | FP 100 µg BID 0.243 Liters (Standard Error 0.0411)
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signal
NCT02924688: Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001).
NCT04937387: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF) (Baseline (pre-dose at Day 1) and Week 12): Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug 0.136 Liters (Standard Error 0.0316) vs Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug 0.078 Liters (Standard Error 0.0321)
Fluticasone Furoate / Vilanterol (Breo Ellipta)ApprovedSmall moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptorReliable signal
NCT01086384: Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010
NCT03248128: Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (FEV1) (0-4 Hours) at Week 12 in 5-17 Year Old Population (Week 12): Participants Who Received FF/ VI FDC 2.082 Liters (Standard Deviation 0.7598) vs Participants Who Received FF 1.994 Liters (Standard Deviation 0.6998)
Fluticasone PropionateApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Fluticasone Propionate / Salmeterol (Advair Diskus)ApprovedSmall moleculeGlucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT00920959: Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) missed
Fluticasone Propionate / Salmeterol (Advair HFA)ApprovedCombinationGlucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptorPartial signal
NCT00448435: Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53)
Levalbuterol (Xopenex HFA)Approved—beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Mepolizumab (Nucala)ApprovedMonoclonal antibodyIL-5, Interleukin-5 (IL-5), ligand-neutralizingWeak signal
NCT01691508: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66
NCT01000506: Number of Clinically Significant Exacerbations of Asthma Per Year (From randomization (Week 0) to Week 52 or early withdrawal (EW)): Mepolizumab 75 mg IV 1.24 Exacerbations per year | Mepolizumab 250 mg IV 1.46 Exacerbations per year | Mepolizumab 750 mg IV 1.15 Exacerbations per year vs Placebo IV 2.4 Exacerbations per year
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mometasone Furoate / Formoterol Fumarate (Dulera / Zenhale)ApprovedSmall moleculeGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00383240: Primary endpoint (FEV1 AUC(0-12h) change from baseline to week 12, L*h), MF/F 200/10 mcg vs MF 200 mcg alone: 3.19 (SD 3.98) vs 1.31 (SD 3.98); p<.001.
NCT00383552: AUC(0-12h) change from baseline to Week 12 in FEV1: MF/F 100/10 mcg BID +4.00 L*h (SD 3.71) vs MF 100 mcg BID +2.53 L*h (SD 3.71); ANCOVA p=0.001.
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEWeak signalNo reviewed efficacy summary in this indication
Primatene MistApprovedSmall moleculeAdrenergic receptor (non-selective, alpha+beta), Alpha-1 and beta-1/beta-2 adrenergic receptors, Adrenergic receptors, nonselectivePartial signal
NCT01460511: Primary endpoint, AUC0-6h of percent change in FEV1 at week 4: numerical benefit of epinephrine HFA over placebo, not statistically significant (two-sided p=0.125, per-protocol analysis; supported by the ITT and three sensitivity analyses). FDA judged the trial underpowered. missed
NCT01357642: Primary endpoint, AUC0-6h of percent change in FEV1 at week 12 (ITT): epinephrine HFA 250 mcg 40.59 (SD 56.09, n=248) vs placebo 12.76 (SD 55.77, n=61); mean difference 27.83 (95% CI 11.99 to 43.68), p<0.05. Epinephrine CFC active control: 35.67 (SD 45.70, n=64).
Salmeterol (DISKUS)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
TerbutalineApprovedSmall moleculeBeta-2 adrenergic receptor (ADRB2)not yet gradedNo reviewed efficacy summary in this indication
Tezepelumab (Tezspire)ApprovedMonoclonal antibodyTSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizingReliable signal
NCT03347279: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39)
NCT03406078: Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control (Baseline to Week 48): Tezepelumab — >=90% to <=100% reduction: 40/74; >=75% to <90% reduction: 5/74; >=50% to <75% reduction: 10/74; >0% to <50% reduction: 5/74; no change or any increase: 14/74 vs Placebo — >=90% to <=100% reduction: 35/76; >=75% to <90% reduction: 4/76; >=50% to <75% reduction: 14/76; >0% to <50% reduction: 9/76; no change or any increase: 14/76 missed
Tiotropium BromideApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Reliable signal
NCT00772538: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026)
NCT00565266: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) (AM PEF was measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.): Tio + 1xICS 24.4 Liters per minute (Standard Error 4.2) vs LABA + 1xICS 18 Liters per minute (Standard Error 3.2) vs 2xICS -1.4 Liters per minute (Standard Error 3.5)
Beclomethasone Dipropionate / Formoterol FumaratePhase 3Small moleculeGlucocorticoid receptor; β2-adrenergic receptorReliable signal
NCT05292586: 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12 (Baseline (pre-dose on Week 0) and Week 12.): CHF 1535 pMDI 0.279 liter (95% CI 0.248 to 0.309) vs CHF 718 pMDI 0.174 liter (95% CI 0.143 to 0.206)
FelcorekibartPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
FenoterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Fenoterol / Ipratropium BromidePhase 3Small moleculeMuscarinic M3 receptor / Beta-2 adrenergic receptor (combination), Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptorReliable signal
NCT02182479: Primary, average FEV1 change from test-day baseline over 6 hours after dosing on day 85, non-inferiority of Respimat SMI (10/25 mcg and 20/50 mcg) vs pMDI (20/50 mcg): neither Respimat dose was inferior to the pMDI (p<0.001), met. Supportive: mean peak FEV1 increase on day 85 was 0.498 to 0.521 L with active treatment vs 0.215 and 0.240 L with placebo.
Indacaterol Maleate / Mometasone FuroatePhase 3—Glucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT02554786: Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016)
NCT02892344: Trough FEV1 (week 12): QMF149 150/80 μg 2.562 Liters (Standard Error 0.0134) | MF 200 µg 2.379 Liters (Standard Error 0.0134)
IpratropiumPhase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesPartial signal
NCT01449162: Annualized severe asthma exacerbation rate (SAER), primary population, overall treatment exposure: masitinib reduced SAER by 35% vs placebo; rate ratio 0.65 (95% CI 0.47-0.90; P=0.010)
NCT03771040: Severe asthma exacerbations: 29% reduction vs placebo (p=0.022) in patients with eosinophils above 150/uL
OcankitugPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
Oxitropium Bromide (Ba253BINEB)Phase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Salbutamol HFA-152aPhase 3Small moleculeBeta-2 adrenergic receptorWeak signal
NCT06261957: Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results).
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VilanterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signal
NCT00600171: Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036)
Glycopyrronium (PT001)Phase 2/3Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT03358147: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412)
StapokibartPhase 2/3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
WIN378Phase 2/3Monoclonal antibodyTSLPWeak signalFeatured results are safety only in this race
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
ARO-RAGEPhase 2RNA / oligonucleotideRAGE (receptor for advanced glycation end-products)Weak signalFeatured results are safety only in this race
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Freneslerbart / MevonlerbartPhase 2Monoclonal antibodyFel d 1 (major cat allergen protein)Reliable signal
NCT03838731: Primary endpoint, time to early asthmatic reaction at Week 1 following single dose: >4 hours (REGN1908-1909) vs 51 minutes (placebo), p=0.0083
FrevecitinibPhase 2Small moleculeJAK1/2/3/TYK2Weak signalNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13Weak signalFeatured results are safety only in this race
PBF-680Phase 2—Adenosine A1 receptorPartial signal
NCT03774290: Trough FEV1 change from baseline at Day 16: placebo 2.88±0.10 L vs PBF-680 3.06±0.09 L; +180 mL mean increase over placebo (P=0.0816, pre-specified alpha=0.1)
QuisovalimabPhase 2Monoclonal antibodyLIGHT (TNFSF14)Partial signal
NCT05288504: Participants with an asthma-related event through week 14: AVTX-002 12 vs placebo 14 (CT.gov posted counts); the sponsor states the primary endpoint was not met. missed
RC1416Phase 2Multispecific antibodyIL-4 / IL-5 / IL-13not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 60 furthest-along competitors are listed; 27 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Montelukast (Singulair) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (8)
January 2027 (1)
Phase 2/3Dengue, Montelukast, TransaminasesRecruiting
Est. primary completion 2027-01 · NCT06747130 · CT.gov ↗
What to watch
February 2027 (3)
Phase 4Allergic Rhinitis (AR)Not yet recruiting
Est. primary completion 2027-02 · NCT07532993 · CT.gov ↗
What to watch
Phase 4AlbuminuriaRecruiting
Est. primary completion 2027-02 · NCT05498116 · CT.gov ↗
What to watch
Phase 3Myocardial Infarction (MI)Recruiting
Est. primary completion 2027-02-01 · NCT07320625 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Acute Myocardial Infarction (AMI)Recruiting
Est. primary completion 2027-05 · NCT07537868 · CT.gov ↗
What to watch
June 2027 (3)
Phase 1ACL Injury, Meniscus Tear, Post-traumatic OsteoarthritisRecruiting
Est. primary completion 2027-06 · NCT04572256 · CT.gov ↗
What to watch
Phase 1/2Bronchopulmonary Dysplasia (BPD), Premature Births, Critical IllnessRecruiting
Est. primary completion 2027-06-01 · NCT07101640 · CT.gov ↗
What to watch
Phase 2Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host DiseaseRecruiting
Est. primary completion 2027-06-30 · NCT05922761 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
Phase 1Gulf War SyndromeRecruiting
Est. primary completion 2028-04 · NCT05992311 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2030-12 · NCT07409714 · CT.gov ↗
What to watch
2031 (1)
June 2031 (1)
Phase 4Diabetes, Kidney Disease, Vascular Disease, RetinopathyNot yet recruiting
Est. primary completion 2031-06-30 · NCT07685886 · CT.gov ↗
What to watch

See the full readout calendar ↗